FT. MYERS, FL --(Marketwired - October 24, 2017) - NeoGenomics, Inc. (
Douglas M VanOort, NeoGenomics Chairman and CEO, stated, "We are very pleased to open our first Laboratory facility outside of the United States as we advance our strategy to be a worldwide leader in Oncology testing and compete in the market for global clinical trials testing. Our Pharma clients have expressed significant interest in the advanced testing services we are offering from this facility such as flow cytometry, fluorescent in-situ hybridization (FISH) and immunohistochemistry (IHC). We greatly appreciate the assistance and incentives we have received from the Canton of Vaud and look forward to strong growth as we expand our business in the European market."
NeoGenomics Europe, S.A. will hold a grand opening ceremony on Wednesday, November 8 from 11:00 to 16:00 at its new Rolle facility, which is located in the A-One Business Center at Z.A. La Pièce 1, Bâtiment 2, 1180 Rolle. Parties interested in attending this ceremony and touring the new facility should contact our marketing department at marketing@neogenomics.com .
About NeoGenomics, Inc.
NeoGenomics, Inc. specializes in cancer genetics testing and information services. The Company provides one of the most comprehensive oncology-focused testing menus in the world for Physicians to help them diagnose and treat cancer. The Company's Pharma Services Division serves pharmaceutical clients in clinical trials and drug development.
Headquartered in Fort Myers, FL, NeoGenomics operates CLIA certified laboratories in Aliso Viejo and Fresno, California; Tampa and Fort Myers, Florida; Houston, Texas and Nashville, Tennessee. NeoGenomics serves the needs of pathologists, oncologists, academic centers, hospital systems, integrated service delivery networks, and managed care organizations throughout the United States. For additional information about NeoGenomics, visit www.neogenomics.com .
Forward Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in the foregoing are forward-looking statements. These forward-looking statements involve a number of risks and uncertainties that could cause actual future results to differ materially from those anticipated in the forward-looking statements. Actual results could differ materially from such statements expressed or implied herein. Factors that might cause such a difference include, among others, the company's ability to continue gaining new customers, offer new types of tests, and otherwise implement its business plan. As a result, this press release should be read in conjunction with the company's periodic filings with the SEC.
For further information, please contact: NeoGenomics, Inc. Steven C. Jones Director of Investor Relations (239) 325-2001 sjones@neogenomics.com
